New drug combo plus radiation shows promise for tough liver and bile duct cancers
NCT ID NCT03482102
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus radiation therapy for people with advanced liver cancer (hepatocellular carcinoma) or bile duct cancer (biliary tract cancer). The goal is to see how many patients' tumors shrink or disappear. The study involves 37 participants and tracks side effects. It is currently active but no longer recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.